DCH
Dauch Corporation
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeDauch's Q3 2026 results featured a nearly doubled revenue base ($2.91B) driven by the $1.41B Dowlais acquisition contribution, which beat sales estimates but came with a $45.3M net loss on the deal and a lowered full-year EBITDA outlook due to accounting adjustments. Concurrent CFO transition (May to CAO; Iles incoming December 1) adds execution risk during a critical post-merger integration phase, while analyst consensus has downshifted $2 to $9.30 on near-term margin concerns despite some voices citing long-term synergy upside.
Red flags
- •Adjusted EPS declined 27% YoY ($0.22 vs $0.30) despite 92% revenue growth, indicating margin pressure from acquisition
- •$45.3M net loss on Dowlais deal signals near-term integration costs and valuation/accounting headwinds
- •Full-year 2026 EBITDA guidance lowered post-earnings despite raised sales guidance, reflecting margin deterioration
- •Consensus analyst price target cut by $2 to $9.30 since earnings; Jefferies downgrade to Hold (Sept 23) reflects skepticism on near-term returns
- •CFO transition during major post-acquisition integration introduces execution and continuity risk
- •Dowlais contribution only partial-year (Q3 only), creating visibility and modeling uncertainty for FY27
Fund 13D/13G Filings (2)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Greenlight Capital | SC 13G/A | +6.0M | 7.7% | -7.1% vs SPY -10.3% abs | 2026-11-16 | ↗ |
| Greenlight Capital | SC 13G | NEW | 5.2% | -28.7% vs SPY -30.9% abs | 2026-08-14 | ↗ |